化合物PD-1/PD-L1-IN-9 T9651
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 9
- 0
Product IntroductionBioactivity英文名: PD-1/PD-L1-IN-9描述: PD-1/PD-L1-IN-9 是一种有效和具有口服活性的 PD-1/PD-L1 相互作用抑制剂，IC50 值为 3.8 nM。PD
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: PD-1/PD-L1-IN-9
描述: PD-1/PD-L1-IN-9 是一种有效和具有口服活性的 PD-1/PD-L1 相互作用抑制剂，IC50 值为 3.8 nM。PD-1/PD-L1-IN-9 可以增强免疫细胞对肿瘤细胞的杀伤活性。PD-1/PD-L1-IN-9 在 CT26 小鼠模型中表现出显着的体内抗肿瘤活性。
体外活性: PD-1/PD-L1-IN-9（46.9-1500 nM；预处理2小时）剂量依赖性地显著激活了PBMCs对MDB-MB 231细胞的抗肿瘤免疫力，EC50约为100 nM[1]。
体内活性: PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 90 mg/mL (258.3 mM)
关键字: PD-1/PD-L1-IN-9 | PD1/PDL1IN9 | PD 1/PD L1 IN 9
相关产品: Eciskafusp alfa | PD-1/PD-L1-IN-10 | CAY10678 | IMMH 010 maleate | BMS-1001 hydrochloride | PD-1/PD-L1-IN-31 | Tomivosertib | HE-S2 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | Reozalimab
相关库: Anti-Breast Cancer Compound Library | Anti-Cancer Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | PPI Inhibitor Library | Bioactive Compound Library
Bioactivity
英文名: PD-1/PD-L1-IN-9
描述: PD-1/PD-L1-IN-9 是一种有效和具有口服活性的 PD-1/PD-L1 相互作用抑制剂，IC50 值为 3.8 nM。PD-1/PD-L1-IN-9 可以增强免疫细胞对肿瘤细胞的杀伤活性。PD-1/PD-L1-IN-9 在 CT26 小鼠模型中表现出显着的体内抗肿瘤活性。
体外活性: PD-1/PD-L1-IN-9（46.9-1500 nM；预处理2小时）剂量依赖性地显著激活了PBMCs对MDB-MB 231细胞的抗肿瘤免疫力，EC50约为100 nM[1]。
体内活性: PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 90 mg/mL (258.3 mM)
关键字: PD-1/PD-L1-IN-9 | PD1/PDL1IN9 | PD 1/PD L1 IN 9
相关产品: Eciskafusp alfa | PD-1/PD-L1-IN-10 | CAY10678 | IMMH 010 maleate | BMS-1001 hydrochloride | PD-1/PD-L1-IN-31 | Tomivosertib | HE-S2 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | Reozalimab
相关库: Anti-Breast Cancer Compound Library | Anti-Cancer Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | PPI Inhibitor Library | Bioactive Compound Library
猜你喜欢
感兴趣产品